PARIS, Feb. 16, 2012 /CNW/ - Echosens announces the acquisition of BioLiveScale, a company specialising in biomarkers for liver diseases.
BioLiveScale has rapidly grown to become a key player in the diagnosis of liver diseases.
Its acquisition by Echosens will lead to rapid internationalisation of its leading product, FibroMetre.
According to Richard Guillaume, Chief Executive Officer of Echosens, the acquisition will solidify Echosen's position as a leading international key player in the non-invasive diagnosis of liver diseases.
This development will also enable BioLiveScale to boost its international development thanks to Echosen's structure and organisation; it already sells FibroScan® in over 70 countries.
Of note is the fact that FibroScan® revolutionised the discipline of hepatology through its unique patented technology using vibration-controlled transient elastography (VCTE) which enables the liver's stiffness to be measured in a non-invasive way.
Liver stiffness is a diagnostic and prognostic marker for chronic liver conditions such as hepatitis B and C, metabolic diseases, alcohol-related issues, etc.
This non-invasive technique is reproducible, operator independent and is particularly suitable for patient diagnosis and follow-up.
Echosens is a French high-tech medical company founded in 2001. It designed, developed, and markets FibroScan®. FibroScan® is used for the non-invasive diagnosis of the liver and is used in over 1,300 clinical sites worldwide.
For further information:
Chief Executive Officer